Portal de Periódicos da CAPES

Pharmacodynamic Studies with a Specific α2-Adrenoceptor Agonist (BHT-933) in Man

1982; Lippincott Williams & Wilkins; Volume: 4; Issue: 4 Linguagem: Inglês

10.1097/00005344-198207000-00001

1533-4023

Peter C. Rubin, Colin W. Howden, Kathleen McLean, John L. Reid,

Blood Pressure and Hypertension Studies

We conducted pharmacodynamic studies in man with a specific α2-adrenoceptor agonist BHT-933. The study involved nine male normotensive volunteers each of whom received BHT-933 5 mg or placebo in random order. BHT-933 significantly lowered systolic and diastolic blood pressure (BP) in supine and standing positions, the greatest effect occurring 3–4 h following drug administration. Supine values: placebo 116/73; BHT-933 99/64. Standing values: placebo 114/79: BHT-933 92/67. Heart rate was uninfluenced by BHT-933 even at the time of maximum fall in BP. Plasma noradrenaline concentration in the supine position was significantly reduced: placebo 2.5 ± 0.8 nmol/L: BHT-933 1.7 ± 0.6. The haemodynamic changes accompanying Valsalva's manoeuvre and cold pressor test were uninfluenced by BHT-933. All subjects experienced sedation and dry mouth following BHT-933 with a time course similar to that of the fall in BP. These results are consistent with an effect of BHT-933 on BP control through an action on α2-receptors at the level of the brainstem.